PMID- 19759185
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20220419
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 21
IP  - 3
DP  - 2010 Mar
TI  - Stanford V program for locally extensive and advanced Hodgkin lymphoma: the 
      Memorial Sloan-Kettering Cancer Center experience.
PG  - 574-581
LID - S0923-7534(19)38300-0 [pii]
LID - 10.1093/annonc/mdp337 [doi]
AB  - BACKGROUND: The Stanford group has reported excellent results with the Stanford V 
      regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, 
      Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V 
      to other regimens but included major deviations from the original program. We 
      retrospectively examined whether treatment at our institution carefully following 
      Stanford V guidelines would confirm the original Stanford outcome data. PATIENTS 
      AND METHODS: From June 1995 to May 2002, 126 patients with either locally 
      extensive or advanced HL were treated with the 12-week Stanford V chemotherapy 
      program followed by 36-Gy involved-field radiotherapy to sites initially > or =5 
      cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 
      20% had international prognostic score (IPS) > or =4. Overall survival (OS), 
      disease-specific survival, progression-free survival (PFS), FFS, and freedom from 
      second relapse (FF2R) were determined. RESULTS: The 5- and 7-year OS were 90% and 
      88%, respectively. The 5-year FFS was 78%. IPS > or =4 was a significant 
      independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. 
      CONCLUSION: Stanford V with appropriate radiotherapy is a highly effective 
      regimen for locally extensive and advanced HL.
FAU - Edwards-Bennett, S M
AU  - Edwards-Bennett SM
AD  - From the Lymphoma Disease Management Team and Department of Radiation Oncology 
      and Department of Radiation Oncology.
FAU - Jacks, L M
AU  - Jacks LM
AD  - Medicine.
FAU - Moskowitz, C H
AU  - Moskowitz CH
AD  - Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      NY, USA.
FAU - Wu, E J
AU  - Wu EJ
AD  - From the Lymphoma Disease Management Team and Department of Radiation Oncology 
      and Department of Radiation Oncology.
FAU - Zhang, Z
AU  - Zhang Z
AD  - Medicine.
FAU - Noy, A
AU  - Noy A
AD  - Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      NY, USA.
FAU - Portlock, C S
AU  - Portlock CS
AD  - Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      NY, USA.
FAU - Straus, D J
AU  - Straus DJ
AD  - Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      NY, USA.
FAU - Zelenetz, A D
AU  - Zelenetz AD
AD  - Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      NY, USA.
FAU - Yahalom, J
AU  - Yahalom J
AD  - From the Lymphoma Disease Management Team and Department of Radiation Oncology 
      and Department of Radiation Oncology. Electronic address: yahalomj@mskcc.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090916
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/drug therapy/radiotherapy/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/radiotherapy/*therapy
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Salvage Therapy
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/09/18 06:00
MHDA- 2010/05/14 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
AID - S0923-7534(19)38300-0 [pii]
AID - 10.1093/annonc/mdp337 [doi]
PST - ppublish
SO  - Ann Oncol. 2010 Mar;21(3):574-581. doi: 10.1093/annonc/mdp337. Epub 2009 Sep 16.